Trial reportThe Journal of investigative dermatology2015
Topical Mineralocorticoid Receptor Blockade Limits Glucocorticoid-Induced Epidermal Atrophy in Human Skin.
Trial report in The Journal of investigative dermatology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01407471 (Interest of Topical Spironolactone's Administration to Prevent Corticoid-induced Epidermal Atrophy), which is not on this map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Interest of Topical Spironolactone's Administration to Prevent Corticoid-induced Epidermal Atrophy
Who cites it
25 citing papers in PubMed, 55 citations in OpenAlex.
- Effects of Intermittent Treatment with Topical Corticosteroids and Calcineurin Inhibitors on Epidermal and Dermal Thickness Using Optical Coherence Tomography and Ultrasound.Skin pharmacology and physiology · 2022Trial
- Erianin Targets PINK1/Parkin-Mediated Mitophagy and Apoptosis to Ameliorate Atopic Dermatitis.Food science & nutrition · 2026Article
- Cross-species transcriptomics identify mineralocorticoid receptor pathway overactivation as a central driver of ocular rosacea.Nature communications · 2026Article
- Emerging roles for endothelial mineralocorticoid receptor in disease pathogenesis: potential new indications for mineralocorticoid receptor antagonism.Current opinion in physiology · 2026Article
- Korean Red Ginseng attenuates glucocorticoid-induced skin barrier dysfunction via mineralocorticoid receptor modulation.Journal of ginseng research · 2026Article
- The role of the mineralocorticoid receptor in skin.Molecular and cellular endocrinology · 2025Review
- The Effect of Glucocorticoid and Mineralocorticoid Receptor Antagonists in the Skin of Aged Female Mice.International journal of molecular sciences · 2025Article
- A Combination of Anatolian Propolis and Curcumin Protects Fibroblasts Against Beclomethasone (Nazal Steroid)-Induced Oxidative Stress by Modulating IL-25, MMP-2, VEGF, and FGF-2 Expressions.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Extra-adrenal aldosterone: a mini review focusing on the physiology and pathophysiology of intrarenal aldosterone.Endocrine · 2024Review
- The myeloid mineralocorticoid receptor regulates dermal angiogenesis and inflammation in glucocorticoid-induced impaired wound healing.British journal of pharmacology · 2022Article
- Characterization of a novel non-steroidal glucocorticoid receptor agonist optimized for topical treatment.Scientific reports · 2022Article
- The long winding road to the safer glucocorticoid receptor (GR) targeting therapies.Oncotarget · 2022Review
- Topical Treatment of Human Skin and Cultured Keratinocytes with High-Dose Spironolactone Reduces XPB Expression and Induces Toxicity.JID innovations : skin science from molecules to population health · 2021Article
- The significance of CYP11A1 expression in skin physiology and pathology.Molecular and cellular endocrinology · 2021Article
- A novel mineralocorticoid receptor antagonist, 7,3',4'-trihydroxyisoflavone improves skin barrier function impaired by endogenous or exogenous glucocorticoids.Scientific reports · 2021Article
- Multiple subcutaneous haematomas of the legs causing skin necrosis in an elderly patient affected by corticosteroid-induced skin atrophy: Case report and review of literature.International wound journal · 2020Review
- Spironolactone and XPB: An Old Drug with a New Molecular Target.Biomolecules · 2020Review
- Glucocorticoid-Induced Skin Atrophy: The Old and the New.Clinical, cosmetic and investigational dermatology · 2020Review
- Spironolactone Depletes the XPB Protein and Inhibits DNA Damage Responses in UVB-Irradiated Human Skin.The Journal of investigative dermatology · 2019Article
- Roles of the Glucocorticoid and Mineralocorticoid Receptors in Skin Pathophysiology.International journal of molecular sciences · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 10 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A major deleterious side effect of glucocorticoids is skin atrophy. Glucocorticoids activate the glucocorticoid and the mineralocorticoid (MR) receptor, both present in the epidermis. We hypothesized that glucocorticoid-induced epidermal atrophy may be related to inappropriate occupancy of MR by glucocorticoids. We evaluated whether epidermal atrophy induced by the topical glucocorticoid clobetasol could be limited by coadministration of MR antagonist. In cultured human skin explants, the epidermal atrophy induced by clobetasol was significantly limited by MR antagonism (canrenoate and eplerenone). Blockade of the epithelial sodium channel ENaC by phenamil was also efficient, identifying a role of MR-ENaC cascade in keratinocytes, acting through restoration of clobetasol-induced impairment of keratinocyte proliferation. In the SPIREPI randomized double-blind controlled trial, gels containing clobetasol, the MR antagonist spironolactone, both agents, or placebo were applied on four zones of the forearms of 23 healthy volunteers for 28 days. Primary outcome was histological thickness of the epidermis with clobetasol alone or clobetasol+spironolactone. Spironolactone alone did not affect the epidermal thickness but coapplication of clobetasol and spironolactone significantly limited clobetasol-induced atrophy and was well tolerated. Altogether, these findings identify MR as a factor regulating epidermal homeostasis and suggest that topical MR blockade could limit glucocorticoid-induced epidermal atrophy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.